FDA launches AI pilot for drug trials to shape regulatory standards

Investing.com - The Food and Drug Administration announced a pilot program on Tuesday to evaluate the use of artificial intelligence in regulatory decision-making for drug and biologic development. The notice will be formally published in the Federal Register on April 29 as FR Doc. 2026-08281.

The program opens a 30-day window through May 29 for sponsors to apply to participate. The FDA will select a limited number of companies to submit specific AI use cases across preclinical and early clinical development, particularly in Phase I applications. Use cases include translational modeling, dose selection, early trial design, and biomarker strategies supporting the transition from nonclinical findings to first-in-human studies.

The FDA will work with selected participants interactively to assess model credibility, validation, and fitness for purpose. The goal is to build practical experience and develop consistent internal frameworks for evaluating AI-generated evidence rather than to approve AI tools directly. The pilot program will be guided by principles aligned with the National Institute of Standards and Technology AI Risk Management Framework.

The pilot aims to explore how AI and data science can improve trial efficiency, enhance safety monitoring, facilitate dose selection decisions, and enable more informed early go/no-go decisions. The program addresses early-phase clinical trials, which the FDA characterized as a critical bottleneck in drug development often marked by high uncertainty, limited patient populations, and inefficient decision-making processes.

Evercore ISI analyst Elizabeth Anderson said the pilot represents a "logical next step from the FDA" and begins to define a workable pathway for AI use in clinical development. The analyst expects AI adoption to be gradual, with near-term timelines driven by the pilot window and follow-on guidance, and longer-term uptake dependent on individual pharma and biotech decision-making over two or more years.

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• enVVeno Medical (NVNO) files $100M mixed shelf
• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner